Melanotan 2 dosage and half-life records

Human dose records

The dose-escalation pilot in three healthy men escalated subcutaneous Melanotan II from 0.01 to 0.025–0.03 mg/kg. Somnolence limited escalation at 0.03 mg/kg. The controlled erection study in 10 men used 0.025 mg/kg subcutaneously. These are amounts administered within those experiments.

A bare figure can give me an impression of authority that its supporting trial scarcely earns. The population, route, supervision and measured outcome gave each figure its research context. Melanotan 2 has no approved indication and no established safe human dosage; this page provides no personal dosing plan.

Melanotan 2 injections: experimental routes

The food-motivation experiment in male mice used 0.1, 0.3 or 1 nanomole per side within the nucleus accumbens. The female-rat sexual-behaviour experiment used 1 and 3 mg/kg intravenously in hormone-primed animals. Other appetite and thermogenesis experiments delivered the compound centrally in rodents.

Where a compound is administered changes the biological question. Intracerebral and intravenous experiments cannot be converted into instructions for human subcutaneous use by arithmetic on body weight. An animal amount quoted without its route earns very little trust from me.

Melanotan 2 half life

A validated human pharmacokinetic half-life for Melanotan II itself has not been published in this record. The rat pharmacokinetic study showed rapid, biphasic plasma clearance after intravenous administration. That describes a fast initial phase followed by a slower one in rats.

The often-borrowed human figures come from Melanotan I, the linear analogue. Its reported absorption-phase half-life was 0.07–0.79 hours and its beta-phase half-life was 0.8–1.7 hours after subcutaneous administration. Oral administration produced no detectable plasma levels in that human Melanotan I study. The name of the tested compound is doing crucial work in that sentence.

I would strike out a confident human Melanotan II half-life if its supporting paper actually measured the other analogue. The missing direct measurement remains missing.

Pigmentation after blood levels fall

In the human Melanotan I pharmacokinetic work, pigmentation persisted for weeks despite rapid peptide clearance. A blood concentration and a downstream pigment response run on different clocks. The observation concerns Melanotan I and supplies context rather than a timing rule for Melanotan II.

Users also describe prolonged and uneven fading in the online-discussion literature. Those anecdotal accounts establish no reliable duration for another person. The effects file includes the mole changes and other symptoms discussed alongside them.